MEMPHASYS LIMITED. — Board/Management Information 2011

Mar 6, 2011

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 25] intentionally omitted <==

==> picture [196 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep strengthens leadership team with appointment of CFO

SYDNEY, AUSTRALIA – 7 March 2011: Emerging life sciences company, NuSep Limited (ASX: NSP), today announced that it has strengthened its leadership team with the appointment of Malcolm Coleman as Chief Financial Officer (CFO).

Mr. Coleman, a Bachelor of Science Graduate with First Class Honours, has over 20 years’ experience in the banking and finance. Most recently he was head of Debt Products at ABN AMRO Australia, and has previously held debt capital markets and treasury roles, including specific experience with treasury hedging products.

NuSep Managing Director, Dr. Hari Nair, said Mr. Coleman’s appointment reflects NuSep’s focus on strengthening its financial skills base as it enters the next phase of growth and international expansion, primarily through its investment in SingaPharm.

“We are delighted to have attracted such a talented senior executive as Malcolm Coleman to NuSep. As we embark on the next stage of our growth, we recognise the need to further strengthen our finance skills base. Also, Malcolm’s experience working across multiple international financial markets fits well with our growth plans in Asia through the proposed SingaPharm investment.”

Malcolm Coleman added: “NuSep is a company on the move, it has completely re-invigorated its product range by utilising internal R&D and has exciting sales plans ahead. This is a great opportunity to apply my finance experience and be part of a senior team building a premier Australian medical technology company.”

Malcolm Coleman commenced with NuSep on 21 February 2011.

.

ENDS

For more information please contact:

Contact: Prakash Patel Company Secretary +61 2 8197 3377 prakash.patel@nusep.com

Released through : Fergus Ross, Six Degrees Investor Communication: +61 420 980 448

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.

NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066

Postal Address P.O. Box 823 Lane Cove NSW 1595

Contact Details Email info@nusep.com Telephone +61 2 8415 7300 Web www.nusep.com Facsimile +61 2 8415 7399 ABN 33 120 047 556

– 2 –

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 10] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative ɳUView Gels, which can be visualised 2 minutes after use.

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.

• Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm’s process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm’s process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.